Last reviewed · How we verify
NCT02839291: PRISM
Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
NA trial testing quality of life questionaries in Tumor With Bone Metastasis in 148 participants. Participants enrolled and being followed up; not accepting new ones.
5 February 2024
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 148 |
| Start date | 14 June 2016 |
| Primary completion | 5 February 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 2 locations across France |
Drugs / interventions tested
- quality of life questionaries
- intravenous or oral bone antiresorptive treatments — full drug profile →
Conditions studied
- Tumor With Bone Metastasis — all drugs for Tumor With Bone Metastasis →
Sponsor
Centre Hospitalier Universitaire de Besancon
Who can join
18 and older, any sex, with Tumor With Bone Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.
Gdowski AS, Ranjan A, Vishwanatha JK. · · 2017 · cited 83× · PMID 28800754 · DOI 10.1186/s13046-017-0578-1 -
Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets.
Wen J, Li B, Wang S, Yao Y, et al · · 2026 · PMID 41660304 · DOI 10.1002/mco2.70604
Verify or expand the search:
- PubMed search for NCT02839291
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire de Besancon trials
Trials by the same sponsor.
- NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
- NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
- NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02839291 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
- Last refreshed: 27 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02839291.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing